TO:           ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS              FROM:      PROTOCOL SECTION

DATE:       JUNE 17, 2019

RE:           PROTOCOL NRG-GY012 – CLOSURE

 

Protocol Title: “A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.”

NCI Version: January 15, 2019
Study Chair: Helen Mackay, MD 
helen.mackay@sunnybrook.ca

Effective immediately June 17, 2019; NRG-GY012 is closed to patient entry. The study has met the accrual goal.

Twitter
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse
View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.